Brain biomarkers were long hard to pin down. See how new Parkinson's and Alzheimer's biomarkers are changing that.

Over the past decade, a succession of new GvHD treatments targeting different components of the immune response have been ...

Find out what came out of the World Conference on Lung Cancer (WCLC) 2026, from late-stage successes and failures to earlier-stage promise.

Discover how GLP-1 drugs are being studied for potential new indications, from autoimmune diseases and addiction to Parkinson’s and MASH.

AstraZeneca has set itself the goal of reaching $80 billion in annual revenue by 2030, up from $58.7 billion in 2025. Its oncology business continues to grow, but AstraZeneca is also looking to newer ...

For a long time, neurological drug development has largely focused on the cells that ultimately die or malfunction. Alzheimer’s researchers chased amyloid and tau. Parkinson’s drug development ...